Novo Nordisk completes its acquisition of Akero; efruxifermin joins its MASH pipeline

Novo Nordisk/Efruxifermin

Novo Nordisk closed its purchase of Akero Therapeutics, which became a wholly owned subsidiary and left the Nasdaq. Shareholders received $54 a share in cash plus a right to $6 more per share on US approval of efruxifermin for compensated cirrhosis due to MASH.

• Aggregate value: $4.7B in cash plus up to $0.5B in contingent value rights.
• Akero's stock stopped trading on the Nasdaq Global Select Market.
• Efruxifermin's three Phase 3 SYNCHRONY trials continue under Novo.